Metastatic Castration Resistant Prostate Cancer Clinical Trial
— PRESIDEOfficial title:
A Randomized, Double Blind, Placebo-Controlled, Phase IIIb Study of the Efficacy and Safety of Continuing Enzalutamide in Chemotherapy Naïve Metastatic Castration Resistant Prostate Cancer Patients Treated With Docetaxel Plus Prednisolone Who Have Progressed on Enzalutamide Alone
Verified date | March 2024 |
Source | Astellas Pharma Inc |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of the study was to understand if there was benefit in continued treatment with a medicine called enzalutamide, when starting treatment with docetaxel and prednisolone (a standard chemotherapy for prostate cancer), after the prostate cancer had gotten worse when treated with enzalutamide alone.
Status | Completed |
Enrollment | 688 |
Est. completion date | March 13, 2024 |
Est. primary completion date | April 30, 2020 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Histologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features; - Ongoing androgen deprivation therapy (ADT) with a luteinizing hormone-releasing hormone (LHRH) agonist or antagonist at a stable dose and schedule within 4 weeks of initiation of investigational medicinal product (IMP), or bilateral orchiectomy (i.e., surgical or medical castration); - Metastatic disease documented by at least 2 bone lesions on bone scan, or soft tissue disease documented by computed tomography (CT)/magnetic resonance imaging (MRI); - Progressive disease at study entry defined as the following occurring in the setting of castrate levels of testosterone: Prostate specific antigen (PSA) progression defined by a minimum of three rising PSA levels with an interval of = 1 week between each determination. - Asymptomatic or minimally symptomatic prostate cancer (Brief Pain Inventory - Short Form (BPI-SF) question 3 score of < 4); - Eastern Cooperative Oncology Group (ECOG) performance score of 0-1; - Estimated life expectancy of = 12 months; - Be suitable and willing to receive chemotherapy as part of the trial; - Able to swallow the IMP and comply with study requirements; - Subject agreed not to participate in another interventional study while on treatment. Exclusion Criteria: - Prior treatment with the following agents for the treatment of prostate cancer: Aminoglutethimide; Ketoconazole; Abiraterone; Enzalutamide or participation in a clinical trial of enzalutamide; 223Ra, 89Sr, 153Sm, 186Re/188Re; Immunomodulatory therapies; Cytotoxic chemotherapy; Participation in a clinical trial of an investigational agent that inhibits the AR or androgen synthesis unless the treatment was placebo; - Current or prior treatment within 4 weeks prior to initiation of investigational medicinal product (IMP) with the following agents for the treatment of prostate cancer: Antiandrogens; 5-a reductase inhibitors; Estrogens; Anabolic steroids; Drugs with antiandrogenic properties; Progestational agents; - Subject had received investigational therapy within 28 days or 5 half-lives whichever was longer, prior to initiation of IMP; - Use of opiate analgesia for pain from prostate cancer within 4 weeks prior to initiation of IMP; - Radiation therapy to bone lesions or prostatic bed within 4 weeks prior to initiation of IMP; - Major surgery within 4 weeks prior to initiation of IMP; - History of seizure or any condition that may predispose to seizures at any time in the past. History of loss of consciousness or transient ischemic attack within 12 months prior to Screening; - Known or suspected brain metastasis or active leptomeningeal disease; - History of another malignancy within the previous 5 years other than non-melanoma skin cancer; - Clinically significant cardiovascular disease; - Gastrointestinal disorders affecting absorption; - Medical contraindications to the use of prednisolone or docetaxel; - Allergies to any of the active ingredients or excipients in the study drugs |
Country | Name | City | State |
---|---|---|---|
Austria | Site AT43004 | Linz | |
Austria | Site AT43001 | Vienna | |
Belgium | Site BE32003 | Bonheiden | |
Belgium | Site BE32002 | Liege | |
Belgium | Site BE32004 | Ottignies | |
Czechia | Site CZ42004 | Brno | |
Czechia | Site CZ42003 | Olomouc | |
Czechia | Site CZ42002 | Plzen -Lochotín | |
Czechia | Site CZ42001 | Praha 2 | |
France | Site FR33012 | Albi | |
France | Site FR33003 | Montpellier | |
France | Site FR33002 | Nîmes | |
France | Site FR33008 | Paris | |
France | Site FR33014 | Paris | |
France | Site FR33004 | Plerin | |
France | Site FR33013 | Quimper | |
France | Site FR33011 | Reims | |
France | Site FR33005 | Suresnes | |
Germany | Site DE49008 | Aachen | |
Germany | Site DE49010 | Bergisch Gladbach | |
Germany | Site DE49001 | Hannover | |
Germany | Site DE49006 | Heidelberg | |
Germany | Site DE49003 | Mannheim | |
Germany | Site DE49002 | Munster | |
Germany | Site DE49018 | Nürtingen | Baden-Württemberg |
Germany | Site DE49015 | Tübingen | |
Germany | Site DE49017 | Ulm | |
Germany | Site DE49004 | Wuppertal | |
Greece | Site GR30003 | Athens | |
Greece | Site GR30006 | Athens | |
Greece | Site GR30001 | Heraklion | Crete |
Greece | Site GR30004 | Heraklion | Crete |
Greece | Site GR30005 | Thessaloniki | |
Italy | Site IT39001 | Arezzo | |
Italy | Site IT39012 | Brescia | |
Italy | Site IT39003 | Milano | |
Italy | Site IT39008 | Naples | |
Italy | Site IT39010 | Pavia | |
Italy | Site IT39005 | Roma | |
Italy | Site IT39004 | Rome | |
Italy | Site IT39002 | Terni | |
Netherlands | Site NL31002 | Amsterdam | |
Netherlands | Site NL31007 | Blaricum | |
Netherlands | Site NL31004 | Hoofddorp | |
Netherlands | Site NL31010 | Nieuwegein | |
Netherlands | Site NL31003 | Rotterdam | |
Norway | Site NO47005 | Drammen | |
Norway | Site NO47001 | Kristiansand | |
Norway | Site NO47004 | Stavanger | |
Poland | Site PL48004 | Gdansk | |
Poland | Site PL48003 | Krakow | |
Poland | Site PL48002 | Lodz | |
Poland | Site PL48005 | Warszawa | |
Poland | Site PL48006 | Warszawa | |
Russian Federation | Site RU70001 | Moscow | |
Russian Federation | Site RU70002 | Moscow | |
Russian Federation | Site RU70003 | Moscow | |
Russian Federation | Site RU70004 | Obninsk | Kaluga |
Russian Federation | Site RU70005 | St. Petersburg | |
Russian Federation | Site RU70006 | St. Petersburg | |
Spain | Site ES34005 | Lugo | |
Spain | Site ES34001 | Madrid | |
Spain | Site ES34002 | Madrid | |
Spain | Site ES34003 | Madrid | |
Spain | Site ES34010 | Madrid | |
Spain | Site ES34007 | Malaga | |
Spain | Site ES34009 | Murcia | |
Spain | Site ES34008 | Santander | |
Spain | Site ES34004 | Sevilla | |
Spain | Site ES34006 | Valencia | |
Sweden | Site SE46002 | Göteborg | |
Sweden | Site SE46005 | Kalmar | |
Sweden | Site SE46003 | Solna | |
Sweden | Site SE46004 | Uppsala | |
Switzerland | Site CH41005 | Locarno | Tessin |
Switzerland | Site CH41009 | Zurich | |
Turkey | Site TR90001 | Ankara | |
Turkey | Site TR90003 | Istanbul | |
Turkey | Site TR90002 | Izmir | |
United Kingdom | Site GB44010 | Aberdeen | |
United Kingdom | Site GB44004 | Cambridge | |
United Kingdom | Site GB44018 | Cardiff | |
United Kingdom | Site GB44014 | Exeter | |
United Kingdom | Site GB44003 | London | |
United Kingdom | Site GB44020 | Northwood | |
United Kingdom | Site GB44015 | Norwich | |
United Kingdom | Site GB44002 | Nottingham | |
United Kingdom | Site GB44017 | Swansea | |
United Kingdom | Site GB44007 | Wirral |
Lead Sponsor | Collaborator |
---|---|
Astellas Pharma Europe Ltd. | Medivation LLC, a wholly owned subsidiary of Pfizer Inc. |
Austria, Belgium, Czechia, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Russian Federation, Spain, Sweden, Switzerland, Turkey, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Progression Free Survival (PFS) | PFS: time from randomization (Period 2 Week 1) to earliest progression event. Progression is defined as radiographic progression, unequivocal clinical progression, or death on study. Radiographic progression is defined for bone disease by appearance of = 2 new lesions on whole-body radionuclide bone scan per Prostate Cancer Clinical Trials Working Group 2 (PCWG2) criteria (i.e., unconfirmed progressive disease) that needs to be confirmed in the next assessment (i.e., progressive disease in the next assessment) or for soft tissue disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Unequivocal clinical progression is defined as new onset cancer pain requiring chronic administration of opiate analgesia or deterioration from prostate cancer of Eastern Cooperative Oncology Group (ECOG) performance status score to = 3, or initiation of subsequent lines of cytotoxic chemotherapy or radiation therapy or surgical intervention due to complications of tumor progression. | From date of randomization to the earliest of either documented disease progression (median duration: 35 weeks) | |
Secondary | Time to Prostate-specific Antigen (PSA) Progression | Time to PSA progression, defined as the time from randomization (Period 2 Week 1) to the date of the first PSA value in Period 2 demonstrating progression (Period 2). The PSA progression date is defined as the date that a = 25% increase and an absolute increase of = 2 ng/mL above the nadir recorded in Period 2 is documented, which must be confirmed by a second consecutive value obtained at least 3 weeks later. | From date of randomization to the first PSA value (median duration: 35 weeks) | |
Secondary | Prostate-specific Antigen (PSA) Response | PSA response, defined as a decrease in percentage change from randomization (Period 2 Week 1) of 50% or more. PSA response was derived at Week 13 and at any time after randomization in Period 2. PSA response at any time is defined as a decrease in percentage change from randomization (Period 2 Week 1) at any time after randomization of 50% or more. Percentage of participants with PSA response was reported. | Randomization, Week 13, any time after randomization in Period 2 (median of 35 weeks) | |
Secondary | Objective Response Rate (ORR) | ORR, defined as the best overall radiographic response after randomization (Period 2 Week 1) as per Investigator assessments of response for soft tissue disease per RECIST 1.1, in participants who had a measurable tumor. ORR was reported as the percentage of participants with complete response (CR) or partial response (PR). CR was defined as disappearance of all target and nontarget lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to < 10 mm from baseline measurement. PR was defined as at least a 30% decrease in the sum of diameters (longest for nonnodal lesions, short axis for nodal lesions) of target lesions taking as reference to the baseline sum of diameters. | From date of randomization up to median duration of 35 weeks | |
Secondary | Time to Pain Progression | The time to an increase of >=30% from randomization (Period 2 Week 1) in average BPI-SF item scores (items 3, 4, 5, 6) at two consecutive evaluations >=3 weeks apart without decrease in analgesic score according to the World health Organization (WHO). Only participants with an average pain intensity item score >=4 were considered. The BPI-SF was an instrument to document pain-related functional impairment and contains 7 questions which included pain intensity [(items 3, 4, 5 and 6): worst pain, least pain, average pain and current pain, with scales from 0 (no pain) to 10 (pain as bad as you can imagine)] and pain interference ](items 9A to 9G): general activity, mood, walking ability, normal work, relations with other people, sleep and enjoyment of life, with scales from 0 (does not interfere) to 10 (completely interferes)]. The BPI-SF total score for pain intensity was calculated as the mean of the 4 scores for the 4 items of pain intensity. | From date of randomization up to median duration of 35 weeks | |
Secondary | Time to Opiate Use for Cancer-related Pain | Time to opiate use for cancer-related pain, defined as the time from randomization (Period 2 Week 1) to initiation of chronic administration of opiate analgesia [parenteral opiate use for =7 days or use of WHO Analgesic Ladder Level 3 oral opiates for =3 weeks]. | From date of randomization up to median duration of 35 weeks | |
Secondary | Time to First Skeletal-related Event (SRE) | Time to first SRE, defined as the time from randomization (Period 2 Week 1) to radiation therapy or surgery to bone, pathologic bone fracture, spinal cord compression, or change of antineoplastic therapy to treat bone pain. | From date of randomization up to median duration of 35 weeks | |
Secondary | Change From Baseline in Functional Assessment of Cancer Therapy - Prostate (FACT-P) | FACT-P quality of life questionnaire is a multi-dimensional, self-reported quality of life instrument specifically designed for use with prostate cancer participants. It consists of 27 core items which assess participant function in four domains rated on 0 to 4 Likert-type scale: physical well-being (PWB) (7 items; 0 [worst] to 4 [better], score range 0-28), social/family well-being (SWB) (7 items; 0 [worst] to 4 [better], score range 0-28), emotional well-being (EWB) (6 items; 0 [worst] to 4 [better], score range 0-24), and functional well-being (FWB) (7 items; 0 [worst] to 4 [better], score range 0-28), which is further supplemented by 12 site-specific items to assess for prostate-related symptoms (Prostate Cancer Subscale [PCS] 12 items rated on Likert-type scale 0 [worst] to 4 [better], score range 0-48). The total domain scores and PCS subscale score are then combined to a global quality of life score ranging between 0 to 156; higher scores representing better quality of life. | Period 2: Baseline, weeks 1, 13, 25, 37, 49, 61, 73, 85, 97, 109, 121, 133, 145, 157, 169, 181 | |
Secondary | Change From Baseline in EuroQOL 5-dimension 5-level Questionnaire [EQ-5D-5L] Visual Analog Scale (VAS) | The EQ-5D-5L VAS records the participant's self-rated health on a vertical visual analogue scale, where the endpoints are labelled from 0 (worst health imaginable) to 100 (best health imaginable). | Period 2: Baseline, weeks 1, 13, 25, 37, 49, 61, 73, 85, 97, 109, 121, 133, 145, 157, 169, 181 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02495974 -
European Observational Study of Enzalutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
|
||
Completed |
NCT03641560 -
A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy
|
Phase 4 | |
Terminated |
NCT02441517 -
A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel Treatment
|
Phase 4 | |
Active, not recruiting |
NCT03454750 -
Radiometabolic Therapy (RMT) With 177Lu PSMA 617 in Advanced Castration Resistant Prostate Cancer (CRPC)
|
Phase 2 | |
Completed |
NCT03776968 -
A Study Evaluating HC-1119 Single-Dose Pharmacokinetics and Effect of Food on Its Pharmacokinetics
|
Phase 1 | |
Completed |
NCT02471469 -
Personalizing Enzalutamide Therapy by Understanding the Relation Between Tumor mRNAs, miRNAs and Treatment Response
|
||
Terminated |
NCT03177187 -
Combination Study of AZD5069 and Enzalutamide.
|
Phase 1/Phase 2 | |
Terminated |
NCT03531827 -
Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment
|
Phase 2 | |
Completed |
NCT02566772 -
Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer
|
Phase 1 | |
Completed |
NCT03829436 -
TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
|
Phase 1 | |
Terminated |
NCT05241613 -
A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer
|
Phase 1 | |
Recruiting |
NCT05369000 -
Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant Prostate Cancer (mCRPC) Resistant Prostate Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02975934 -
A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
|
Phase 3 | |
Active, not recruiting |
NCT04869488 -
A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
Completed |
NCT00428220 -
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
|
N/A | |
Completed |
NCT04056754 -
Study of Abiraterone Acetate in Subjects With Metastatic Castration Resistant Prostate Cancer
|
Phase 3 | |
Completed |
NCT03658447 -
PRINCE (PSMA-lutetium Radionuclide Therapy and ImmuNotherapy in Prostate CancEr)
|
Phase 1/Phase 2 | |
Terminated |
NCT03042312 -
Lutetium-177 (Lu177) Prostate-Specific Antigen (PSMA)-Directed EndoRadiotherapy
|
Phase 2 | |
Completed |
NCT02991911 -
A Phase 1/1b Study of MEDI3726 in Adults Subjects With Metastatic Castration Resistant Prostate Cancer
|
Phase 1 | |
Completed |
NCT02655822 -
Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers
|
Phase 1 |